Medindia14h
Fluctuating Body Weight May Increase Kidney Disease Risk in Type 1 Diabetes
Body weight cycling in type 1 diabetes is associated with increased risk of chronic kidney disease. Maintaining stable weight ...
AFP16h
U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that the U.S. Food and Drug Administration (FDA) has approved ROMVIMZA™ (vimseltinib), a kinase ...
Le Lézard18h
U.S. FDA Grants Full Approval of Deciphera's ROMVIMZAtm (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; "Ono") announced that the U.S. Food and Drug Administration (FDA) has approved ROMVIMZAtm (vimseltinib), a kinase ...